You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 12, 2025

Drug Price Trends for MEMANTINE


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for MEMANTINE

Average Pharmacy Cost for MEMANTINE

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
MEMANTINE HCL 10 MG TABLET 72606-0515-04 0.06059 EACH 2025-01-22
MEMANTINE HCL 10 MG TABLET 72606-0515-02 0.06059 EACH 2025-01-22
MEMANTINE HCL 5 MG TABLET 72606-0514-04 0.07387 EACH 2025-01-22
MEMANTINE HCL 5 MG TABLET 72606-0514-02 0.07387 EACH 2025-01-22
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for MEMANTINE

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type
MEMANTINE HCL 14MG CAP,SA AvKare, LLC 65162-0783-09 90 114.43 1.27144 EACH 2023-06-15 - 2028-06-14 FSS
MEMANTINE HCL 21MG CAP,SA AvKare, LLC 65162-0784-03 30 38.14 1.27133 EACH 2023-06-15 - 2028-06-14 FSS
MEMANTINE HCL 28MG CAP,SA AvKare, LLC 65162-0785-03 30 38.14 1.27133 EACH 2023-06-15 - 2028-06-14 FSS
MEMANTINE HCL 28MG CAP,SA AvKare, LLC 65162-0785-09 90 114.43 1.27144 EACH 2023-06-15 - 2028-06-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Unit >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Memantine Market Analysis and Price Projections

Overview of Memantine

Memantine is a non-acetyl cholinesterase inhibitor drug primarily used in the treatment of moderate to severe dementia associated with Alzheimer's disease. It received European marketing approval in 2002 and U.S. FDA approval in 2003. Generic versions of the drug have been available since 2015, significantly impacting the market dynamics[1][3][5].

Market Size and Growth

The global memantine market is expected to exhibit substantial growth over the forecast period. Here are some key statistics:

  • The memantine hydrochloride tablets market was valued at USD 0.62 billion in 2023 and is projected to reach USD 1.1 billion by 2032, growing at a CAGR of 5.9%[4].
  • The broader Alzheimer’s disease market, which includes memantine, is anticipated to grow at a strong CAGR of 17.5%, reaching sales of $14.8 billion by 2026. However, memantine's specific contribution will be influenced by the introduction of new therapies such as monoclonal antibody-based immunotherapies and BACE inhibitors[5].

Market Segments

The memantine market is segmented based on several criteria:

By Formulation

  • Memantine is available in various formulations, including tablets, capsules, oral kits, and oral solutions. The extended-release capsules are particularly popular, available in strengths of 7mg, 14mg, 21mg, and 28mg[3][2].

By Distribution Channel

  • The distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. North America, particularly the U.S., holds a dominant position due to the availability of generic versions[1][3].

Regional Analysis

North America

  • This region is expected to maintain its dominant position in the global memantine market, driven by the increasing number of generic versions available in the U.S. market. For instance, Lupin Limited launched its Memantine Hydrochloride Extended-Release Capsules in the U.S. in 2018[3].

Asia-Pacific

  • The Asia-Pacific region is expected to witness significant growth due to the increasing focus of key players in manufacturing memantine tablets. Dr. Reddy’s Laboratories, for example, launched memantine hydrochloride tablets in the Indian market in 2018[3].

Latin America and Middle East & Africa

  • These regions also show potential for growth, although at a slower pace compared to North America and Asia-Pacific. The increasing prevalence of Alzheimer’s disease and growing awareness are driving factors in these regions[1].

Competitive Analysis

The memantine market is highly competitive, with several key players:

  • Merz Pharmaceuticals: Known for its original brand, Namenda.
  • Lupin Limited: Launched generic versions of memantine in the U.S. market.
  • Allergan plc: Involved in the distribution and marketing of memantine products.
  • Novartis AG, Daiichi Sankyo Company, Ono Pharmaceutical Co Ltd., Eisai Co., Ltd., H. Lundbeck A/S, Dr. Reddy's Laboratories, and Johnson & Johnson Services, Inc. are other significant players in the market[1][3].

Price Projections

The prices of memantine vary based on the formulation and quantity:

Oral Capsules

  • Extended-release capsules: Prices range from $49.03 for 30 capsules to $1,727.34 for 500 capsules, depending on the strength (7mg, 14mg, 21mg, 28mg)[2].

Oral Tablets

  • Immediate release tablets: Prices range from $29.90 for 30 tablets (5mg) to $5,587.49 for 3000 tablets (10mg)[2].

Oral Kits and Solutions

  • Oral kits: Prices start from $263.64 for 49 kits.
  • Oral solutions: Prices start from $261.19 for 240 milliliters[2].

Driving Factors

Several factors are driving the growth of the memantine market:

  • Increasing Prevalence of Alzheimer’s Disease: The global prevalence of Alzheimer’s disease is increasing, which in turn drives the demand for memantine.
  • Aging Population: The aging population is more susceptible to Alzheimer’s disease, contributing to the market growth.
  • Advancements and Awareness: Increasing awareness and advancements in treatment options are also driving the market[4].

Challenges and Restraints

Despite the growth, the memantine market faces several challenges:

  • Competition from New Therapies: The introduction of new therapies such as monoclonal antibody-based immunotherapies and BACE inhibitors could reduce the market share of memantine.
  • Generic Competition: The availability of generic versions of memantine has reduced the prices and profitability for branded versions[5].

Future Trends and Developments

The memantine market is expected to evolve with several trends:

  • Launch of New Products: Pipeline products, including immunotherapies and BACE inhibitors, will enter the market, potentially altering the treatment landscape.
  • Geographical Expansion: Key players are expanding their operations in emerging markets, particularly in Asia-Pacific.
  • Increased Focus on Generic Versions: The availability and affordability of generic versions will continue to shape the market dynamics[1][3][5].

Key Takeaways

  • The memantine market is growing due to increasing prevalence of Alzheimer’s disease and aging population.
  • North America and Asia-Pacific are key regions driving the market growth.
  • Generic versions of memantine are widely available, impacting the pricing and market dynamics.
  • New therapies are expected to enter the market, potentially changing the treatment landscape.

FAQs

What is the projected market size of the memantine hydrochloride tablets market by 2032?

The memantine hydrochloride tablets market is expected to reach USD 1.1 billion by 2032[4].

What is the CAGR of the memantine hydrochloride tablets market?

The memantine hydrochloride tablets market is expected to exhibit a CAGR of 5.9% by 2032[4].

Which regions are expected to drive the growth of the memantine market?

North America and Asia-Pacific are expected to be the key drivers of the memantine market growth[1][3].

What are the different formulations of memantine available in the market?

Memantine is available in tablets, capsules, oral kits, and oral solutions[3][2].

How does the competition from new therapies impact the memantine market?

The introduction of new therapies such as monoclonal antibody-based immunotherapies and BACE inhibitors could reduce the market share of memantine, although memantine will remain a significant treatment option due to its established presence and affordability[5].

Sources

  1. OpenPR: Memantine Market advancements Highlighted by Demand, Business Growing Strategies and Forecast 2031.
  2. Drugs.com: Memantine Prices, Coupons, Copay Cards & Patient Assistance.
  3. Coherent Market Insights: Memantine Market Size, Trends And Forecast To 2028.
  4. Business Research Insights: Memantine Hydrochloride Tablets Market Trends, Forecast, 2032.
  5. GlobalData: MARKET BRIEF - Alzheimer's Disease Market Report (2016-2026).

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.